Gland Pharma Ltd. GLAND

Gland Pharma posts strong Q1 FY27 results with 47% PAT surge, unveils major manufacturing agreement and strategic collaborations to drive ~20% CAGR growth.

Apotex Health Corp. ("Apotex") (TSX: APTX) today announced the U.S. launch of four product configurations of its generic equivalents of Infuvite® Pediatric Injection and Infuvite® Adult Injection. Of the four configurations launched, the Adult Bulk and Pediatric Single presentations received Competitive Generic Therapy (CGT) exclusivity.

Gland Pharma Ltd (NSE:GLAND) reports a strong Q4 with 22% revenue growth, driven by CDMO business and US market expansion.

Apothecon Group, a regulated markets-focused, speciality formulations business, today announced the appointment of Shyamakant Giri as the Group Chief Executive Officer, effective May 11, 2026. Based out of Vadodara, India, Mr. Giri will lead the next phase of growth and strategic expansion for the Group.

Apotex, in collaboration with Orbicular Pharmaceutical Technologies Pvt. Ltd. and Gland Pharma Limited, today announced that the U.S. Food and Drug Administration (FDA) has approved the Abbreviated New Drug Application (ANDA) for generic Infuvite® Pediatric Injection, which is eligible for 180‑day Competitive Generic Therapy (CGT) exclusivity for single dose vial. Apotex is the ANDA sponsor and will lead commercialization in the United States.

Apotex Corp., in partnership with Orbicular Pharmaceutical Technologies Pvt. Ltd. and Gland Pharma Limited, today announced that the U.S. Food and Drug Administration (FDA) has approved two Abbreviated New Drug Application (ANDA) for generic Infuvite® Adult Injection (Single Dose and Pharmacy Bulk Package), with eligibility for 180‑day Competitive Generic Therapy (CGT) exclusivity for the pharmacy bulk package. Apotex is the ANDA applicant and will lead commercialization in the United States.

Gland Pharma Ltd (NSE:GLAND) reports robust financial performance with significant product launches and expansion plans, despite margin pressures.